Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings

Travere Therapeutics (TVTX) reported $41.37 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 27.4%. EPS of -$1.76 for the same period compares to -$1.27 a year ago.

The reported revenue represents a surprise of -2.70% over the Zacks Consensus Estimate of $42.52 million. With the consensus EPS estimate being -$0.98, the EPS surprise was -79.59%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Travere performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Tiopronin products / Thiola: $20.15 million compared to the $22.62 million average estimate based on eight analysts. The reported number represents a change of -4.8% year over year.
  • Revenue- FILSPARI: $19.83 million versus $17.10 million estimated by seven analysts on average.
  • Revenue- License and collaboration revenue: $1.39 million compared to the $4.58 million average estimate based on five analysts. The reported number represents a change of -79.3% year over year.
View all Key Company Metrics for Travere here>>>

Shares of Travere have returned -11.1% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

Only $1 to See All Zacks' Buys and Sells

We're not kidding.

Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.

Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Travere Therapeutics, Inc. (TVTX) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.